{
  "docId": "019de077-72f9-7549-be02-1cb8598bb783",
  "docSlug": "e2ad68eb257d4e7a3f142ed0c8be9c7f",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 36,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "timeline",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a dual-track timeline approach to show the progression from observational data collection to clinical trial phases.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-72f9-7549-be02-1cb8598bb783/21",
  "deckHref": "/decks/019de077-72f9-7549-be02-1cb8598bb783",
  "deckJsonHref": "/decks/019de077-72f9-7549-be02-1cb8598bb783.json",
  "deckAnchorHref": "/decks/019de077-72f9-7549-be02-1cb8598bb783#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.22,
        "y": 0.955
      },
      "kind": "disclaimer",
      "text": "*Subject to continued U.S. government funding and timelines",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9fd2c775-ea3f-43b4-8bc4-cbd0be2f6358",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.92,
        "x": 0.036,
        "y": 0.55
      },
      "kind": "framework",
      "text": "Timeline of clinical milestones from 2024 to 2027",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "960b44b0-e2e9-44b2-afa0-c647949a5e59",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.43,
        "x": 0.088,
        "y": 0.317
      },
      "kind": "list",
      "text": "200 patients enrolled at 3 sites in 12 months (Thailand and Laos); Confirmed high mortality (~27% 28-day; ~50% 90-day all-cause)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e9ea48a-ffe6-4b3a-84a6-9d46bd6190ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.33,
        "x": 0.64,
        "y": 0.317
      },
      "kind": "list",
      "text": "Primary endpoint is to evaluate mortality (epetaborole + ceftazidime/meropenem vs. placebo + ceftazidime/meropenem)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5544365f-daa4-4163-981d-ce40808643ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.23,
        "x": 0.036,
        "y": 0.215
      },
      "kind": "title",
      "text": "Planned timeline",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5dc12395-e7af-4230-96b9-91ef923fc234",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.025,
        "y": 0.04
      },
      "kind": "title",
      "text": "Goal to Significantly Reduce Mortality in Melioidosis Treated Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae4c50ec-2bc3-4f34-8b59-9789328619d6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "b161f5c9-a6c2-455a-ba96-d86c344276ee",
      "evidence": "Visual representation of project phases over a calendar timeline.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 21,
      "from": 18,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "944abad7-bde8-4f0c-bdc1-5248c2eb0f53",
      "evidence": "The deck presents the high mortality rate of Melioidosis and the need for new treatments",
      "position": 0,
      "objective": "Highlight the need for new treatments for Melioidosis",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}